Latest Advances

  • Journal: Scientific reports
  • Published —
HLA-B27 is associated with reduced disease activity in axial spondyloarthritis.
  • Condition: Enthesitis in Patients with Axial Spondyloarthritis (SpA)
  • Journal: Arthritis research & therapy
  • Treatment Used: Tumor Necrosis Factor Inhibitors (TNFis)
  • Number of Patients: 1668
  • Published —
This study investigated the evolution of enthesitis following tumor necrosis factor inhibitor (TNFi) initiation in the treatment of patients with spondyloarthritis (spinal arthritis; SpA).
  • Condition: Axial Spondyloarthritis (axSpA)
  • Journal: Current rheumatology reports
  • Treatment Used: JAK Inhibitors (JAKis)
  • Number of Patients: 0
  • Published —
This article discusses the possible role of JAK inhibitors (JAKis) as new medications for the treatment of patients with axial spondyloarthritis (axSpA).
  • Condition: Spondyloarthritis
  • Journal: Medicine
  • Treatment Used: Golimumab as Second Biological Drug
  • Number of Patients: 210
  • Published —
This study evaluated the effectiveness of golimumab as a second biological drug for the treatment of patients with spondyloarthritis.
  • Condition: Axial Spondyloarthritis (axSpA)
  • Journal: Advances in rheumatology (London, England)
  • Treatment Used: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Number of Patients: 0
  • Published —
This article provides guidelines for the treatment of patients with axial spondyloarthritis (axSpA) with nonsteroidal anti-inflammatory drugs (NSAIDs).
  • Journal: Archives of osteoporosis
  • Published —
A 2-year longitudinal study of bone health in adolescent patients with axial spondyloarthritis.
  • Journal: BMJ (Clinical research ed.)
  • Published —
Axial spondyloarthritis: new advances in diagnosis and management.
  • Condition: Axial Spondyloarthritis
  • Journal: PloS one
  • Treatment Used: Tumor Necrosis Factor A Inhibitors (TNFi)
  • Number of Patients: 16
  • Published —
This study evaluated the impact of tumor necrosis factor a inhibitors (medicines that suppress the body's natural response to tumor necrosis factor, a protein produced by white blood cells that is involved in early inflammatory events; TNFi) in patients with axial spondyloarthritis (chronic, autoinflammatory disease predominantly affecting the axial skeleton, which is the central axis of the body and includes the bones of the skull, ossicles of the middle ear, hyoid bone of the throat, vertebral column, and the ribcage).
  • Condition: Axial Spondyloarthritis
  • Journal: Rheumatology (Oxford, England)
  • Treatment Used: NSAIDs
  • Number of Patients: NULL
  • Published —
The study researched treatment of axial spondyloarthritis.
  • Condition: Axial Spondyloarthritis
  • Journal: RMD open
  • Treatment Used: Secukinumab
  • Number of Patients: 1860
  • Published —
This study explored the effectiveness of 6-month and 12-month secukinumab in patients with axial spondyloarthritis (spinal degeneration; axSpA).
  • Condition: Axial Spondyloarthritis
  • Journal: Arthritis research & therapy
  • Treatment Used: TNF Inhibitors
  • Number of Patients: 193
  • Published —
This study investigated if switching TNF inhibitors after a primary or secondary failure provides good clinical outcomes in patients with axial spondyloarthritis.
  • Condition: Axial Spondyloarthritis
  • Journal: International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • Treatment Used: Serial Locally Applied Water-filtered Infrared a Radiation (sl-wIRAR)
  • Number of Patients: 71
  • Published —
In this study, researchers evaluated the outcomes of using serial locally applied water-filtered infrared A radiation (sl-wIRAR) for the treatment of axial spondyloarthritis.
Showing 1-12 of 40